The purity of adeno-associated virus (AAV) vector preparations has important implications for both safety and efficacy of clinical gene transfer. Early-stage screening of candidates for AAV-based therapeutics ideally requires a purification method that is flexible and also provides vectors comparable in purity and potency to the prospective investigational product manufactured for clinical studies. The use of cesium chloride (CsCl) gradient-based protocols provides the flexibility for purification of different serotypes; however, a commonly used first-generation CsCl-based protocol was found to result in AAV vectors containing large amounts of protein and DNA impurities and low transduction efficiency in vitro and in vivo. Here, we describe and characterize an optimized, secondgeneration CsCl protocol that incorporates differential precipitation of AAV particles by polyethylene glycol, resulting in higher yield and markedly higher vector purity that correlated with better transduction efficiency observed with several AAV serotypes in multiple tissues and species. Vectors purified by the optimized CsCl protocol were found to be comparable in purity and functional activity to those prepared by more scalable, but less flexible serotype-specific purification processes developed for manufacture of clinical vectors, and are therefore ideally suited for pre-clinical studies supporting translational research.
Introduction
Over the past several years, many protocols for the purification of recombinant adeno-associated virus (AAV) vectors have been established. [1] [2] [3] [4] [5] [6] [7] An early challenge for AAV production and purification was to obtain sufficient amounts of high-titer vectors to support research studies in animal models. With steady advances in the field into clinical studies, and the isolation of several novel AAV serotypes, 8 more efficient and versatile production and purification methods have been required. An important objective is to ensure that vector preparations used during the early stages of translational research (for example, screening of candidate vector constructs and serotypes) are comparable with respect to purity and functional activity to those used for investigational new drug-supporting studies (for example, pharmacology/toxicology studies) and clinical trials.
Currently, AAV vectors are typically purified by gradient centrifugation or column chromatography. Gradient centrifugation with cesium chloride (CsCl) or iodixanol provides flexibility because a single method can often be used to purify different AAV serotypes. A limitation of gradient centrifugation is the difficulty in scale-up required for clinical product development. In contrast, column chromatography-based vector purification can achieve efficient AAV particle purification and be easily adapted for large-scale production, but chromatography resins and conditions must be uniquely developed and tailored for different serotypes, and efficient removal of vector-related impurities such as empty capsids is difficult. 5 The establishment of a robust and flexible purification method that can be used to prepare different vectors with high purity and potency, comparable to vector quality attributes required for clinical studies, is an important objective for core laboratories supporting early-stage translational research. Serotype-independent methods should complement scalable, serotype-specific purification methods needed for vectors that advance as investigational products.
Additional challenges for successful translation of AAV gene transfer protocols to clinical studies have been described recently. Immunogenicity of AAV capsid was reported to be responsible for short-lived expression of the coagulation factor IX (F.IX) transgene observed in a clinical study of liver-mediated AAV-2 gene transfer for hemophilia B. 9, 10 Additionally, evidence for dosedependent activation of capsid-specific T cells was also reported by our group in the context of AAV-1 intramuscular gene transfer for lipoprotein lipase deficiency. 11, 12 In contrast, in clinical studies in which smaller amounts of AAV vectors were introduced into immunoprivileged body compartments, limited or no immune responses to the AAV capsid were observed. [13] [14] [15] [16] These data support that the route of administration and the total antigen load (that is total vector capsid dose) determine the kinetics and the nature of the immune response against the AAV capsid. Increasing the transgene expression efficiency, vector transduction efficiency, and vector purity, with the objective to minimize viral antigen dose and minimize potentially antigenic moieties, are important approaches to reduce the potential for deleterious host immune responses after vector administration. In this study, we describe and characterize an optimized, second-generation CsCl gradient-based purification method that results in high AAV vector purity and functional activity. We show that, compared with a standard, first-generation, CsCl gradient method, 17 the inclusion of an AAV precipitation step before gradient centrifugation enhanced purification yield and resulted in a marked reduction of DNA and protein impurities that correlated with significant in vivo serotype-and target tissue-independent improvements in transduction efficiency.
Results
A second-generation, optimized gradient centrifugation method for purification of recombinant AAV Precipitation of AAV vector particles by polyethylene glycol (PEG) 8000 before the first ultracentrifugation step was found to effectively separate AAV particles from a significant amount of impurities present in clarified lysates of transfected HEK293 cells. On the basis of spectrophotometric analysis, the addition of 8% PEG8000 resulted in quantitative precipitation of vector, but precipitated only 21.7 and 25.2% of total OD 260 and OD 280 absorbing material, respectively, from clarified cell lysates. This indicated separation of vector from the major portion (470%) of nucleic acid and protein impurities present in the clarified cell culture supernatant. The PEG precipitation step also enabled recovery of vector from clarified cell lysates and tissue culture supernatant (an amount ranging from 10 to 50% of total vector at the time of cell collection, data not shown), and concentrated the vector sufficiently so that fewer tubes were used and visible AAV particle bands were observed after ultracentrifugation. The amount of hF.IX vectors typically generated in X10 roller bottles (RBs) (X5 Â 10 13 vg) resulted in two clearly visible bands corresponding to the lighter AAV empty capsids (B1.3 g cm
À3
) and genome-containing vectors (B1.4 g cm À3 ) ( Figure 1a) . The visualization of vector bands achieved through concentration of vector by the PEG precipitation step before the first CsCl ultracentrifugation eliminated the need for fractionation, refractometry, and dot-blot or quantitative polymerase chain reaction (Q-PCR) analysis of vector genome content in isolated fractions, 17 and enabled more precise recovery of vector bands. Purity assessment by SDS-PAGE followed by silver staining confirmed efficient removal of protein impurities. To the limit of detection of silver staining (B1 ng), the optimized AAV preparations contained virtually no detectable protein other than the expected capsid VP1, VP2, and VP3 bands (Figure 1b, lane 3) . On the basis of the vector loading used (5 Â 10 9 vg per lane; corresponding to B31 ng AAV capsid protein), non-capsid protein impurities correspond to o3% in the optimized CsCl process vector, a purity level comparable to AAV purified by the combined column-gradient method (lanes 1-2). In contrast, AAV purified by the standard CsCl protocol showed markedly higher amounts of protein impurities (Figure 1b, lanes 4-8) .
Spectrophotometric analysis of vector preparations by determination of optical density at 260 and 280 nm in excess of absorbances accounted for by the vector itself was used to provide an quantitative estimate of the of nucleic acid and protein impurities in various vector preparations. A limitation of this approach is the significant overlap in absorbance spectra for nucleic acids and proteins. Hence, for vector preparations containing heterogeneous nucleic acid and protein impurities, OD 260 and OD 280 are expected to provide a good estimate of the total amount of impurities present, but limited ability to distinguish the relative 9 vg plasmid DNA) compared to vector purified by the optimized protocol (100 pg per 10 9 vg: 76.0 ± 43.3 pg per 10 9 vg HEK293 DNA; 23.9 ± 13.6 pg per 10 9 vg plasmid DNA) ( Table 1) . Levels of protein and DNA impurities observed with the optimized CsCl protocol were comparable to those measured in vector purified by the column-gradient method. In addition to the higher purity achieved, overall recovery was improved B1.8-fold by the optimized CsCl method (Table 2) .
High-purity recombinant AAV vectors show serotype-independent enhanced muscle transduction in vivo after direct intramuscular injection in mice
To compare the biological activity of the AAV vectors purified according to the two CsCl purification protocols, 2 Â 10 10 vg of an AAV-1 vector expressing GFP were 
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Alternate AAV serotypes purified with the optimized protocol show improved hepatocyte transduction efficiency in mice and dogs
To assess whether the improved transduction obtained by the more highly purified AAV vectors was a tissuespecific phenomenon, we measured in vivo liver transduction by AAV vectors purified by the two methods. Mice receiving 5 Â 10 11 vg of an AAV-2 vector carrying the human F.IX transgene under the control of a liver-specific promoter 9 expressed 1.30 mg ml À1 (26%) of normal F.IX levels when injected with an optimized AAV-2 vector preparation, and 0.56 mg ml À1 (11%) with the standard AAV-2 preparation (Figure 3a ). Mice were killed 12 weeks after vector administration and transgene copy number in liver was assessed by real-time quantitative PCR analysis: a fourfold increase in vector gene copy number per diploid genome was documented in mice receiving vectors prepared with optimized vs standard method (Figure 3b ; Po0.001, two preparations tested per purification method). These results support the strong correlation between vector purity and transduction efficiency in multiple tissues.
We also evaluated an AAV-1 vector expressing GFP. The vector was injected intravenously into adult mice (3 Â 10 10 vg per mouse) and the percent of liver transduction was quantified 7 days later. The AAV-1-GFP purified by the standard protocol gave barely detectable transduction in liver, whereas significantly higher hepatocyte transduction (10-fold, P ¼ 0.01) was observed in animals injected with the same construct purified by the improved protocol (Figure 3c) . Similarly, in a large animal model of gene transfer, intravenous administration to normal dogs through the saphenous vein resulted in minimal transduction (o1%) of liver cells by the standard method vector, in contrast B4% of liver transduction was achieved by AAV-1-GFP vector prepared by the improved protocol (Figure 3d ).
Discussion
In this study, we report the characterization of an optimized protocol for the CsCl gradient purification of AAV vectors that includes an AAV particle precipitation step before the first ultracentrifugation step and recovery of vector from production cell culture supernatants. One advantage of the improved method, arising from concentration of AAV particles before gradient ultracentrifugation, is the ability to simply and directly visualize and collect bands corresponding to AAV particles. This eliminates the need for equipment and procedures required for fraction collection, refractometry, and other methods to identify fractions containing vector. A second advantage of the optimized CsCl purification method is enhanced overall yield. The recovery of AAV particles from clarified cell lysates as well as from culture supernatant by precipitation with PEG likely contributes significantly to the B1.8-fold higher average recovery of purified vector per RB achieved through the optimized CsCl method. Vector released into the cell culture supernatant was recently characterized as fully infectious, 18 supporting the importance of its recovery for optimal yield and infectivity.
A third and most important advantage realized with the optimized CsCl purification protocol was the markedly higher purity obtained compared to the standard method. The efficient removal of impurities contained in the clarified HEK293 cell lysate by differential precipitation before the first ultracentrifugation to estimate residual production plasmid DNA) were reduced B6.4-fold, supporting that the two Q-PCR amplicons used for residual DNA measurement underestimate total nucleic acid impurities present in these vector preparations, markedly so in vectors purified by the standard method. The level of vector purity observed with the optimized method was comparable to the purity achieved by a scalable, serotype-specific purification method incorporating both column chromatography and gradient ultracentrifugation that has been used to prepare vector for human clinical studies. 16 The marked reduction in protein and DNA impurities by the optimized CsCl protocol supports that CsCl gradient ultracentrifugation alone, even when performed multiple times in series, may not efficiently separate AAV vector particles from these impurities. Although the density of most protein (o1.30 g cm À3 ) and nucleic acid (41.50 g cm À3 ) impurities is significantly different than the density of vector particles (B1.40 g cm À3 ), their inefficient removal by even two rounds of CsCl ultracentrifugation in the standard process may be attributable to the fact that, in contrast to the larger AAV particles, many of these impurities are of insufficient mass to partition efficiently to their equilibrium positions under the standard conditions of ultracentrifugation.
The studies reported herein show an unexpected characteristic of highly purified AAV preparations: we observed a significant increase in transduction efficiency across multiple serotypes and in multiple tissues compared with vectors prepared by the standard process. This difference was confirmed in mice and, importantly, in dogs, which have been shown to be more representative of humans for dosing. 9 Some investigators have reported low functional activity of AAV vectors prepared by the standard CsCl method, 3 and suggested that CsCl may inactivate the vector. Our side-by-side comparison of vectors prepared by the standard and optimized protocol, both of which involve two rounds of ultracentrifugation in CsCl, supports that lower functional activity correlates with the presence of high levels of residual protein and nucleic acid impurities rather than the use of CsCl per se. The mechanism by which residual protein and/or nucleic acid impurities may inhibit transduction efficiency is unclear. It is possible that the more abundant impurities in vectors prepared by the standard process coat the surface of vector particles, and thereby inhibit target cell binding. The use of AAV vector with increased transduction efficiency in liver and muscle is relevant because these tissues are important targets of gene transfer studies for inherited and metabolic diseases 9, 12, [19] [20] [21] as well as the need for high levels of transgene expression for some applications to achieve therapeutic efficacy. 20, 22 Increasing vector purity and potency is predicted to reduce the risk of deleterious, efficacy-limiting immune responses after administration of recombinant AAV to human subjects, a critical consideration for an inherently immunogenic (that is viral) biologic product that will depend on avoidance of certain immune responses to achieve long-term efficacy. Studies in humans showed that, though low doses of highly purified vector administered to immunoprivileged sites (for example, eye, brain) result in minimal, non-efficacy-limiting immune responses, 15, 16 larger doses of vector administered systemically in hemophilia B subjects 9 resulted in a capsid-specific CD8+ T-cell response that limited F.IX transgene expression. 10 Achieving higher vector purity is predicted to lower immunogenicity of the vector in animal models and humans by reducing the adjuvant effect of potentially immunostimulatory moieties such as residual non-self proteins (for example, excess viral capsids and other non-human proteins) and nucleic acids (for example, CpGs containing plasmid backbone sequences). We have also shown that administration of a dose of 1 Â 10 11 vg per kg of an AAV-1 vector intramuscularly in humans results in a delayed Th2 responses, whereas at a dose of 3 Â 10 11 vg per kg, the response was faster and appeared to involve both CD4+ and CD8+ T cells. 11 This supports that an ability to administer a lower dose of a more potent vector (that is a vector with higher transduction efficiency) may have significant implications in shaping the immunogenicity profile of AAV gene transfer and affecting long-term efficacy in human gene transfer.
For translational research, the evolution of an AAV vector product candidate from discovery and early-stage screening, involving evaluation of various candidates to optimize the genetic construct and capsid delivery vehicle, through clinical trials as an investigational new drug, requires purification method development performed in parallel to meet stage-specific needs. Two important considerations for a vector purification method used at earlier stages is that it be versatile enough to support screening and proof of concept studies, but also provide a vector product that is comparable to the product that is subsequently manufactured with more scalable purification methods to support prospective clinical development. The second-generation optimized CsCl purification method described and characterized herein enables flexible purification of vectors of varying serotypes, and importantly results in consistently high vector purity and potency, and comparable in these attributes to vectors prepared for clinical studies. The use of such improved AAV purification methods for pre-clinical studies, combined with further improvements in expression cassettes, use of self-complementary AAV constructs, 23 more efficient serotypes, 8, 24 and improved delivery techniques are important strategies to meet the need for high levels of therapeutic transgene expression and support successful translational research.
Materials and methods

Animals
Male ICR mice 8-12-weeks old (SER-CBATEG, Barcelona, Spain) were used in all experiments with the exception of Enhancement of AAV transduction efficiency E Ayuso et al the AAV-human factor IX (AAV-hF.IX) liver transduction experiments, for which 8-10-weeks-old male C57Black/6 (Jackson Laboratories, Bar Harbor, MA, USA) were used. Male beagle dogs, 6-12-months old (Isoquimen, Barcelona, Spain), were also used. Animal care and experimental procedures were approved by the Ethics Committee in Animal and Human Experimentation of the Universitat Autònoma de Barcelona and the Institutional Animal Care and Use Committee at the Children's Hospital of Philadelphia.
Recombinant AAV vectors
AAV vectors used in this study were produced by identical methods at the Center of Animal Biotechnology and Gene Therapy at the Universitat Autonoma de Barcelona and at the Center for Cellular and Molecular Therapeutics at the Children's Hospital of Philadelphia. Vectors were generated by helper virus-free transfection of HEK293 cells with three plasmids 25 with modifications. 26 Cells were cultured to 70% confluence in RBs (Corning, Lowell, MA, USA) in DMEM supplemented with 10% FBS and then co-transfected with (1) a vector plasmid carrying the expression cassette flanked by the viral ITRs; (2) a packaging plasmid carrying the AAV rep and cap genes; and (3) a helper plasmid carrying the adenovirus helper functions. The transgenes used in the experiments were GFP under the control of a constitutive promoter, and F.IX under the control of a liver-specific promoter. Three days after transfection, cells were collected and centrifuged at 2500 g for 10 min. Transfected cell culture supernatant was retained for processing at a subsequent step for the optimized CsCl purification protocol described below. The cell pellet was resuspended in 10 ml per RB of lysis buffer (50 mM TrisCl per 150 mM NaCl per 2 mM MgCl 2 , pH 8.0), and lysed by freeze-thaw or microfluidization. Cell lysates were clarified by centrifugation at 2500 g for 30 min and incubated with 100 U ml À1 of benzonase (Novagen, Madison, WI, USA) for 1 h at 37 1C. Vectors were purified by two different methods: (1) a first-generation protocol, 17 referred to as 'standard'; or (2) a secondgeneration protocol, referred to as 'optimized'. Figure 4 provides a flow diagram showing the differences between the standard and the optimized AAV protocols. For the standard protocol, clarified cell lysate (B20 ml per tube) was overlayed onto a CsCl solution prepared by layering 12 ml of 1.3 g cm À3 CsCl on top of 5 ml of 1.5 g cm À3 CsCl and centrifuged (104 000 g, 24 h, 20 1C) in a SW28 rotor (Beckman Coulter, Fullerton, CA, USA). After centrifugation, 1 ml fractions were collected and density determined by refractometry, and fractions with a density corresponding to that of AAV vectors were pooled and subjected to isopycnic separation in a second CsCl ultracentrifugation step (182 000 g, 24 h, 20 1C) in a SW40 rotor (Beckman Coulter). Fractions from the second ultracentrifugation step-containing vector, as determined by Q-PCR, were combined in a dialysis cassette (Pierce, Rockford, IL, USA), and dialyzed overnight in PBS. For the optimized process, a stock solution of 40% PEG 8000 (Sigma, St Louis, MO, USA), 2.5 N NaCl, was added to combined clarified cell lysate and culture supernatant to final concentration of 8%. The solution was then incubated on ice for 2 h, centrifuged at 2500 g for 30 min and the supernatant discarded. The pellet containing the virus was resuspended in a minimal volume (10-20 ml per 100 ml clarified cell lysate input), overlayed onto a CsCl solution and centrifuged in a SW28 rotor as described for the standard protocol. After centrifugation, visible bands corresponding to AAV particles were collected with a 10 ml syringe (Figure 1 ). Under the conditions used for the first CsCl ultracentrifugation, vector particle bands were insufficiently separated to allow their reliable separation, and the bands were collected together with a syringe. Vector particles recovered from the first round ultracentrifugation were pooled and subjected to isopycnic separation by a second CsCl ultracentrifugation step (182 000 g, 24 h, 20 1C) in a SW40 rotor. The second ultracentrifugation resulted in high-resolution separation of the AAV particles facilitating precise visual recovery of the lower band (B1.4 g cm
À3
) corresponding to the genome-containing AAV particles. AAV titer measurement was performed by Q-PCR.
Characterization of impurities in AAV vector preparations
For AAV-hF.IX vector genome quantification, Q-PCR was performed as described earlier, 27 with primers and probes specific for the human F.IX sequence as follows: forward primer: 5 0 CCACTGTGTTGAAACTGGTGTT AAA 3 0 ; reverse primer: 5 0 GCTCTGTATGTTCTGTCTCC TCAAT 3 0 ; probe: 5 0 6FAM-TTCACCTGCGACAACTG NFQ 3
0 . Other transgenes were similarly quantified by Q-PCR with specific primers and probes. Vectors purified by each method were analyzed by SDS-PAGE/ 27 To measure relevant specific nucleic acid impurities, residual plasmid DNA was quantified by Q-PCR with primers and probes specific for the ampicillin resistance gene (Amp R ) common to all plasmids used for rAAV vector generation: forward primer, 5 0 CGCGCCACATAGCAGAACTT 3 0 ; reverse primer, 5 0 CGCCCCGAAGAACGTTT 3 0 ; probe, 5 0 VIC-A AAAGTGCTCATCATTG-NFQ 3 0 , and residual HEK293 host cell DNA was quantified by a TaqMan Gene Expression Assay for 18S rRNA (Applied Biosystems, Foster City, CA, USA), with EcoRI digested genomic DNA used as a standard. The amounts of these specific DNA impurities in vector preparations reported in Table  1 were calculated as the ratio of non-vector DNA (residual HEK293+residual plasmid DNA) to total DNA (vector DNA+residual HEK293 DNA+residual plasmid DNA) where the vector (hF.IX DNA) DNA is 2640 pg per 10 9 vg. Measurements of impurities by spectrophotometry and Q-PCR were performed on multiple vector lots purified by the standard CsCl protocol (n ¼ 5), the optimized CsCl protocol (n ¼ 3), and a combined column chromatography/gradient purification protocol used for the manufacture of clinical grade AAV-2 vectors (n ¼ 3).
In vivo administration of AAV vectors
AAV vectors were diluted in 200 ml of PBS and delivered to mice through tail vein injection. For intramuscular administration in mice the appropriate dose of vector was diluted in 30 ml of sterile PBS and injected directly into the gastrocnemius muscle. For administration to dogs, AAV vectors were diluted in sterile PBS and injected into the saphenous vein. Blood samples in mice were collected by retro-orbital bleeding with heparincoated capillary tubes (Fisher Scientific, Pittsburgh, PA, USA). For tissue collection, dogs and mice were killed and the liver and/or muscle were snap frozen for fluorimetric or Q-PCR analysis, or fixed in 10% formalin for immunohistochemical analysis.
Immunohistochemistry
For detection of GFP, liver and muscle were fixed for 12-24 h in 10% formalin, embedded in paraffin, and sectioned. Sections were incubated overnight at 4 1C with a goat anti-GFP antibody (Abcam ab6673, Cambridge, MA, USA) diluted at 1:300 in 10% donkey serum. As secondary antibody, a 1:300 dilution in 10% donkey serum of biotinylated donkey anti-goat antibody (Santa Cruz, Palo alto, CA, USA) and ABC complex (Vector, Burlingame, CA, USA) were used and developed with 3 0 3 0 -diaminobenzidine (DAB, Sigma) chromogenic substrate.
Fluorimetric assay
For the fluorimetric assay, the entire gastrocnemius muscle or a portion of the liver (500 mg per animal) of injected animals and controls was mechanically disrupted in 2 ml lysis buffer (50 mmol l À1 Tris, 1% Nonidet P40, 0.25% sodium deoxycholate, 150 mmol l À1 NaCl, 1 mmol l À1 EDTA, in PBS, pH 7.4, sterile filtered) and incubated for 10 min at room temperature. After incubation, samples were centrifuged at 10 000 g for 10 min. Supernatant was transferred to a new tube and the GFP content in 100 ml of this solution was measured with a luminescence spectrometer Flx800 (Bio-tek instruments, Winooski, VT, USA) with 488 nm excitation and 512 nm emission wavelengths.
Quantification of liver transduction
For morphometric analysis, livers were obtained and staining for GFP was performed in two sections per lobe from each animal. The percent of liver transduction was calculated by dividing GFP-positive hepatocytes by the total count of hepatocyte nuclei per field. A minimum of 20 fields per liver were captured and counted at a Â 20 magnification through a Nikon Eclipse E800 microscope (Nikon Corp., Tokyo, Japan) connected to an image analyzer (analySIS 3.0, Soft Imaging System Corp., Lakewood, CO, USA). A minimum of three mice per experimental group were analyzed.
Human F.IX ELISA
Plasma concentration of human F.IX was determined as described earlier. 28 Plates were coated overnight at 4 1C with a 1:800 dilution of an anti-F.IX antibody (clone HIX-1, Sigma) in 0.2 M NaHCO 3 . After coating, plates were blocked with 0.05% Tween 20, 6% BSA in PBS and plasma samples were loaded and incubated overnight at 4 1C. An HRP-conjugated anti-F.IX antibody (Cedarlane, Burlington, NC, USA) was used at a dilution of 1:1000 as secondary antibody. Concentration of F.IX was determined against a standard curve made with serial dilutions of pooled human plasma.
Vector genome copy number determination
Real-time Q-PCR was used to determine the vector genome copy number in the liver of injected mice. Tissues were frozen in liquid nitrogen and DNA was extracted with a commercial kit (Qiagen, Valencia, CA, USA). The primers and probe set used for this assay have been described earlier. 29 
Statistical analysis
All values are expressed as mean ± s.d. Differences between groups were compared by Student's t-test. P-values less than 0.05 were considered statistically significant.
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